$TELO
Telomir Pharmaceuticals Inc

2024 Q3 Form 10-Q Financial Statement

#000149315224031606 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $879.7K $758.7K
YoY Change 15.95% 20405.41%
% of Gross Profit
Research & Development $627.4K $594.8K $667.6K
YoY Change 138.93% -10.9% 906.94%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.006M $1.474M $1.426M
YoY Change 529.51% 3.38% 1934.66%
Operating Profit
YoY Change
Interest Expense $25.49K -$124.0K
YoY Change -120.56%
% of Operating Profit
Other Income/Expense, Net $15.45K
YoY Change -102.04%
Pretax Income -$1.449M -$1.550M
YoY Change -6.54% 2111.7%
Income Tax
% Of Pretax Income
Net Earnings -$5.991M -$1.449M -$1.550M
YoY Change 250.06% -6.54% 2111.68%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20 -$0.05 -$0.06
Diluted Earnings Per Share -$0.20 -$0.05 -$0.05
COMMON SHARES
Basic Shares Outstanding 29.61M shares 29.61M shares 27.10M shares
Diluted Shares Outstanding 29.61M shares 29.61M shares 27.10M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.884M $14.60K
YoY Change 12803.49%
Cash & Equivalents $834.6K $1.884M $14.63K
Short-Term Investments
Other Short-Term Assets $87.81K $81.40K
YoY Change 7.87%
Inventory
Prepaid Expenses $77.35K $87.81K
Receivables
Other Receivables
Total Short-Term Assets $1.042M $2.102M $96.10K
YoY Change 340.96% 2087.02%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $5.826M
YoY Change -100.0%
Total Long-Term Assets $0.00 $0.00 $5.826M
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $1.042M $2.102M $96.10K
Total Long-Term Assets $0.00 $0.00 $5.826M
Total Assets $1.042M $2.102M $5.922M
YoY Change -80.41% -64.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $393.8K $1.544M
YoY Change -74.5%
Accrued Expenses $100.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $487.9K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $599.9K $534.2K $2.033M
YoY Change -80.9% -73.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $599.9K $534.2K $2.033M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $599.9K $534.2K $2.033M
YoY Change -80.9% -73.72%
SHAREHOLDERS EQUITY
Retained Earnings -$27.70M -$21.77M
YoY Change
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $442.1K $1.568M $3.889M
YoY Change
Total Liabilities & Shareholders Equity $1.042M $2.102M $5.922M
YoY Change -80.41% -64.51%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$5.991M -$1.449M -$1.550M
YoY Change 250.06% -6.54% 2111.68%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.523M -$769.3K
YoY Change 97.95% 489.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 132.4K 782.5K
YoY Change -83.07% 462.14%
NET CHANGE
Cash From Operating Activities -1.523M -769.3K
Cash From Investing Activities
Cash From Financing Activities 132.4K 782.5K
Net Change In Cash -1.390M 13.20K
YoY Change -10633.33% 51.72%
FREE CASH FLOW
Cash From Operating Activities -$1.523M -$769.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
usd
us-gaap Interest Income Other
InterestIncomeOther
usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
TELO Noncash Interest Expense
NoncashInterestExpense
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
TELO Accrued Offering Expense
AccruedOfferingExpense
usd
TELO Issuance Of Warrants On Related Party Line Of Credit
IssuanceOfWarrantsOnRelatedPartyLineOfCredit
usd
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
25493 usd
us-gaap Interest Income Other
InterestIncomeOther
25493 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
124052 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4338542 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
124052 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1449003 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1550385 usd
us-gaap Net Income Loss
NetIncomeLoss
-7703610 usd
us-gaap Net Income Loss
NetIncomeLoss
-2033322 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29609814 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29609814 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27097294 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27097294 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29443148 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29443148 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27023440 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27023440 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3438204 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5832973 usd
us-gaap Net Income Loss
NetIncomeLoss
-7703610 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1567567 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-937278 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
910000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5950000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2033322 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3889400 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3016570 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1449003 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1567567 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-510215 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-510215 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5950000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1550385 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3889400 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3889400 usd
us-gaap Net Income Loss
NetIncomeLoss
-7703610 usd
us-gaap Net Income Loss
NetIncomeLoss
-2033322 usd
TELO Noncash Interest Expense
NoncashInterestExpense
94 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4338543 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
123958 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-10091 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1139954 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
87100 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3462258 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-769316 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
34126 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
101000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
519475 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
581262 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
132438 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
487914 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5832973 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
910000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5344936 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
782526 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1882678 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13210 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1231 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1419 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1883909 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14629 usd
TELO Accrued Offering Expense
AccruedOfferingExpense
124126 usd
TELO Issuance Of Warrants On Related Party Line Of Credit
IssuanceOfWarrantsOnRelatedPartyLineOfCredit
5950000 usd
us-gaap Payments For Fees
PaymentsForFees
100000 usd
us-gaap Stock Issued1
StockIssued1
2439025 usd
TELO Deferred Finance Costs
DeferredFinanceCosts
5950000 usd
CY2024Q2 us-gaap Cash
Cash
1900000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3500000 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
140000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
500000 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
400000 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
700000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
55667 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3708 usd
us-gaap Variable Lease Cost
VariableLeaseCost
332636 usd
us-gaap Variable Lease Cost
VariableLeaseCost
698600 usd
us-gaap Lease Cost
LeaseCost
388303 usd
us-gaap Lease Cost
LeaseCost
702308 usd
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
400000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.00
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2824057 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2824057 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2774057 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2774057 shares

Files In Submission

Name View Source Status
0001493152-24-031606-index-headers.html Edgar Link pending
0001493152-24-031606-index.html Edgar Link pending
0001493152-24-031606.txt Edgar Link pending
0001493152-24-031606-xbrl.zip Edgar Link pending
ex10-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
telo-20240630.xsd Edgar Link pending
telo-20240630_cal.xml Edgar Link unprocessable
telo-20240630_def.xml Edgar Link unprocessable
telo-20240630_lab.xml Edgar Link unprocessable
telo-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable